Ac-SDKP: The Anti-Fibrotic N-Terminal Fragment of Thymosin Beta-4

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Ac-SDKP?

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is a naturally occurring tetrapeptide present in human plasma, blood cells, and multiple tissues. It is generated by the enzymatic cleavage of thymosin beta-4 (TB-4) by prolyl oligopeptidase (POP, also known as prolyl endopeptidase), which cuts between the proline at position 4 and the aspartate at position 5 of TB-4's N-terminal region. The "Ac" prefix indicates acetylation of the N-terminal serine, a modification that occurs on TB-4 itself and is retained in the cleavage product.

The connection between Ac-SDKP and thymosin beta-4 (TB-500) is significant — it means that some of the biological effects attributed to TB-4 may actually be mediated by this smaller fragment generated through in vivo processing. Ac-SDKP has its own distinct biological profile, particularly in the context of fibrosis prevention and hematopoietic stem cell regulation.

Mechanism of Action

Ac-SDKP exerts its biological effects through several interconnected mechanisms, with anti-fibrotic signaling being the most extensively characterized.

Anti-Fibrotic Mechanisms

• TGF-beta/Smad inhibition: Ac-SDKP inhibits the transforming growth factor beta (TGF-beta) signaling pathway, which is the central driver of fibrosis across virtually all organ systems. Specifically, Ac-SDKP reduces Smad2/3 phosphorylation and nuclear translocation, diminishing transcription of fibrotic genes including collagens, fibronectin, and alpha-smooth muscle actin.
• Fibroblast proliferation inhibition: Ac-SDKP directly inhibits the proliferation of cardiac, renal, and dermal fibroblasts, reducing the cellularity of fibrotic lesions.
• Myofibroblast differentiation blockade: The peptide prevents the phenotypic transition of fibroblasts to myofibroblasts — the activated, contractile, collagen-producing cells that are the primary effector cells in organ fibrosis.
• Collagen synthesis reduction: Ac-SDKP reduces the expression and secretion of collagen types I and III, the predominant collagens deposited in fibrotic tissue.

The ACE Connection

A critical aspect of Ac-SDKP biology is its regulation by angiotensin-converting enzyme (ACE). ACE is the primary enzyme responsible for Ac-SDKP degradation, cleaving the Asp-Lys bond. This means that ACE inhibitor drugs — among the most widely prescribed cardiovascular medications — significantly increase circulating Ac-SDKP levels by blocking its degradation. This observation has led to the hypothesis that some of the cardioprotective and renoprotective benefits of ACE inhibitors may be mediated through Ac-SDKP elevation, rather than solely through angiotensin II reduction.

Hematopoietic Regulation

Ac-SDKP was originally identified as a hematopoietic stem cell (HSC) regulator. It acts as a negative regulator of HSC entry into the S-phase of the cell cycle, effectively keeping a proportion of stem cells in a quiescent (G0) state. This quiescence-promoting activity may protect HSCs from cell-cycle-dependent damage (such as chemotherapy or radiation) and help maintain the stem cell pool over the lifespan.

Research Findings

Cardiac Fibrosis

Extensive preclinical research has demonstrated Ac-SDKP's anti-fibrotic effects in cardiac models. In hypertensive rats, Ac-SDKP infusion prevented left ventricular fibrosis without affecting blood pressure, demonstrating a direct anti-fibrotic effect independent of hemodynamic changes. In myocardial infarction models, Ac-SDKP reduced post-infarct fibrosis and improved cardiac function indices. These findings have been replicated across multiple research groups, lending credibility to the anti-fibrotic claims.

Renal Fibrosis

In models of diabetic nephropathy and unilateral ureteral obstruction, Ac-SDKP reduced renal interstitial fibrosis, tubular atrophy, and inflammatory cell infiltration. Studies demonstrated that the anti-fibrotic effect was mediated primarily through TGF-beta/Smad pathway inhibition and was independent of blood pressure effects.

Pulmonary and Hepatic Fibrosis

More recent research has extended Ac-SDKP's anti-fibrotic effects to lung and liver models. In bleomycin-induced pulmonary fibrosis and carbon tetrachloride-induced hepatic fibrosis models, Ac-SDKP treatment reduced collagen deposition and improved tissue architecture.

Safety and Tolerability

As an endogenous peptide present in normal human plasma, Ac-SDKP has inherent biological compatibility. Animal studies using exogenous Ac-SDKP infusion have not reported significant adverse effects. The hematopoietic effects (stem cell quiescence) are a consideration for clinical development — while potentially protective in some contexts, stem cell cycle suppression could theoretically impair hematopoietic recovery in situations requiring active blood cell production.

The indirect evidence from ACE inhibitor use — which elevates Ac-SDKP levels in millions of patients worldwide — provides some reassurance regarding safety at moderately elevated levels. However, the Ac-SDKP levels achieved by direct peptide administration could exceed those produced by ACE inhibition, and dose-dependent effects have not been characterized in humans.

Regulatory Status

Ac-SDKP is not FDA-approved for any indication. It has not entered formal clinical trials as a standalone therapeutic agent. Research interest continues in the context of fibrotic diseases, which represent a significant unmet medical need across cardiology, nephrology, pulmonology, and hepatology. The compound is available through research peptide suppliers for preclinical investigation.